OncoMatch/Clinical Trials/NCT06318871
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
Is NCT06318871 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Cytokine Induced Memory-like Natural Killer (CIML NK) Cells and Interleukin-2 (IL-2) for renal carcinoma.
Treatment: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells · Interleukin-2 (IL-2) — The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood that is collected and bathed in special proteins to help identify and treat curtained advanced cancers, combined with low dose IL-2, which is a cytokine that activates immune cells, in advanced clear cell renal cell carcinoma and urothelial carcinoma. Names of the study therapies involved in this study are/is: * CIML NK cell therapy (a NK cell therapy) * IL-2 (a type of cytokine)
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Urothelial Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy — clear cell RCC or UC
Participants with clear cell RCC or UC must have progression after prior treatment failure with at least one PD-1/PD-L1 immune checkpoint inhibitor that is FDA approved for treatment of UC or RCC
Must have received: VEGFR inhibitor — renal cell carcinoma
Patients with renal cell carcinoma should also have prior treatment failure with at least one prior VEGFR TKI, or contraindication to VEGFR TKIs as determined by the treating clinician
Must have received: cytotoxic chemotherapy — urothelial carcinoma
Patients with urothelial carcinoma should have either prior treatment failure with ≥1 prior cytotoxic chemotherapy or antibody-drug conjugate
Cannot have received: anti-tumor chemotherapy
Exception: within 2 weeks prior to enrollment (4 weeks for nitrosoureas or mitomycin C)
Participants who have had anti-tumor chemotherapy or other investigational agents within 2 weeks prior to enrollment(4 weeks for nitrosoureas or mitomycin C)
Cannot have received: immunotherapy
Exception: within 4 weeks prior
immunotherapy within 4 weeks prior
Cannot have received: investigational agent
Participants who are receiving any other investigational agents
Lab requirements
Blood counts
absolute neutrophil count ≥1,000/mcL; hemoglobin ≥8g/dL (prior transfusion permitted); platelets ≥75,000/mcL; no laboratory evidence of ongoing hemolysis in opinion of investigator
Kidney function
creatinine ≤ 2.0 OR GFR ≥40 mL/min/1.73 m2 for participants with creatinine levels above institutional ULN
Liver function
total bilirubin ≤ 1.5 × institutional ULN (except if secondary to Gilbert's, then < 3 x ULN); AST(SGOT)/ALT(SGPT) ≤3.0 × institutional ULN
Cardiac function
oxygen saturation ≥ 90% on room air; left ventricular ejection fraction > 40%; NYHA class 2B or better
Participants must meet the following organ and marrow function as defined below: absolute neutrophil count ≥1,000/mcL; hemoglobin ≥8g/dL (prior transfusion permitted); platelets ≥75,000/mcL; total bilirubin ≤ 1.5 × institutional ULN (except if secondary to Gilbert's, then < 3 x ULN); AST(SGOT)/ALT(SGPT) ≤3.0 × institutional ULN; creatinine ≤ 2.0 OR GFR ≥40 mL/min/1.73 m2 for participants with creatinine levels above institutional ULN; oxygen saturation ≥ 90% on room air; left ventricular ejection fraction > 40%; No laboratory evidence of ongoing hemolysis in opinion of investigator
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify